Vol. 3 No. 6 (2023)
Reimbursement Reviews

Mavacamten (Camzyos)

Published June 23, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses mavacamten (Camzyos), 2.5 mg, 5 mg, 10 mg, and 15 mg oral capsules.
  • Indication: For the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association class II to III in adult patients.